Literature DB >> 34416146

Pan-protective anti-alphavirus human antibodies target a conserved E1 protein epitope.

Arthur S Kim1, Natasha M Kafai1, Emma S Winkler1, Theron C Gilliland2, Emily L Cottle2, James T Earnest3, Prashant N Jethva4, Paulina Kaplonek5, Aadit P Shah3, Rachel H Fong6, Edgar Davidson6, Ryan J Malonis7, Jose A Quiroz7, Lauren E Williamson8, Lo Vang9, Matthias Mack10, James E Crowe8, Benjamin J Doranz6, Jonathan R Lai7, Galit Alter5, Michael L Gross4, William B Klimstra2, Daved H Fremont11, Michael S Diamond12.   

Abstract

Alphaviruses are emerging, mosquito-transmitted pathogens that cause musculoskeletal and neurological disease in humans. Although neutralizing antibodies that inhibit individual alphaviruses have been described, broadly reactive antibodies that protect against both arthritogenic and encephalitic alphaviruses have not been reported. Here, we identify DC2.112 and DC2.315, two pan-protective yet poorly neutralizing human monoclonal antibodies (mAbs) that avidly bind to viral antigen on the surface of cells infected with arthritogenic and encephalitic alphaviruses. These mAbs engage a conserved epitope in domain II of the E1 protein proximal to and within the fusion peptide. Treatment with DC2.112 or DC2.315 protects mice against infection by both arthritogenic (chikungunya and Mayaro) and encephalitic (Venezuelan, Eastern, and Western equine encephalitis) alphaviruses through multiple mechanisms, including inhibition of viral egress and monocyte-dependent Fc effector functions. These findings define a conserved epitope recognized by weakly neutralizing yet protective antibodies that could be targeted for pan-alphavirus immunotherapy and vaccine design.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Fc effector; alphavirus; antibody; arthritis; encephalitis; immunity; inhiibtion; mice; pathogenesis; protection

Mesh:

Substances:

Year:  2021        PMID: 34416146      PMCID: PMC8382027          DOI: 10.1016/j.cell.2021.07.006

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   66.850


  74 in total

1.  Blocking monoclonal antibodies specific for mouse IFN-alpha/beta receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic transfection.

Authors:  Kathleen C F Sheehan; Koon Siew Lai; Gavin P Dunn; Allen T Bruce; Mark S Diamond; Jennifer D Heutel; Corazon Dungo-Arthur; Javier A Carrero; J Michael White; Paul J Hertzog; Robert D Schreiber
Journal:  J Interferon Cytokine Res       Date:  2006-11       Impact factor: 2.607

2.  The Fusion glycoprotein shell of Semliki Forest virus: an icosahedral assembly primed for fusogenic activation at endosomal pH.

Authors:  J Lescar; A Roussel; M W Wien; J Navaza; S D Fuller; G Wengler; G Wengler; F A Rey
Journal:  Cell       Date:  2001-04-06       Impact factor: 41.582

3.  Determination of the protective epitopes on the glycoproteins of Venezuelan equine encephalomyelitis virus by passive transfer of monoclonal antibodies.

Authors:  J H Mathews; J T Roehrig
Journal:  J Immunol       Date:  1982-12       Impact factor: 5.422

4.  Chikungunya virus arthritis in adult wild-type mice.

Authors:  Joy Gardner; Itaru Anraku; Thuy T Le; Thibaut Larcher; Lee Major; Pierre Roques; Wayne A Schroder; Stephen Higgs; Andreas Suhrbier
Journal:  J Virol       Date:  2010-06-02       Impact factor: 5.103

5.  Alphavirus neurovirulence: monoclonal antibodies discriminating wild-type from neuroadapted Sindbis virus.

Authors:  J Stanley; S J Cooper; D E Griffin
Journal:  J Virol       Date:  1985-10       Impact factor: 5.103

6.  Biochemical and biological characteristics of epitopes on the E1 glycoprotein of western equine encephalitis virus.

Authors:  A R Hunt; J T Roehrig
Journal:  Virology       Date:  1985-04-30       Impact factor: 3.616

7.  Cross-protective immunity against o'nyong-nyong virus afforded by a novel recombinant chikungunya vaccine.

Authors:  Charalambos D Partidos; Joanna Paykel; James Weger; Erin M Borland; Ann M Powers; Robert Seymour; Scott C Weaver; Dan T Stinchcomb; Jorge E Osorio
Journal:  Vaccine       Date:  2012-05-11       Impact factor: 3.641

8.  Mycophenolic acid inhibits dengue virus infection by preventing replication of viral RNA.

Authors:  Michael S Diamond; Marcus Zachariah; Eva Harris
Journal:  Virology       Date:  2002-12-20       Impact factor: 3.616

9.  Therapeutic administration of a recombinant human monoclonal antibody reduces the severity of chikungunya virus disease in rhesus macaques.

Authors:  Rebecca Broeckel; Julie M Fox; Nicole Haese; Craig N Kreklywich; Soila Sukulpovi-Petty; Alfred Legasse; Patricia P Smith; Michael Denton; Carsten Corvey; Shiv Krishnan; Lois M A Colgin; Rebecca M Ducore; Anne D Lewis; Michael K Axthelm; Marie Mandron; Pierre Cortez; Jonathan Rothblatt; Ercole Rao; Ingo Focken; Kara Carter; Gopal Sapparapau; James E Crowe; Michael S Diamond; Daniel N Streblow
Journal:  PLoS Negl Trop Dis       Date:  2017-06-19

10.  Protective antibodies against Eastern equine encephalitis virus bind to epitopes in domains A and B of the E2 glycoprotein.

Authors:  Arthur S Kim; S Kyle Austin; Christina L Gardner; Adam Zuiani; Douglas S Reed; Derek W Trobaugh; Chengqun Sun; Katherine Basore; Lauren E Williamson; James E Crowe; Mark K Slifka; Daved H Fremont; William B Klimstra; Michael S Diamond
Journal:  Nat Microbiol       Date:  2018-11-19       Impact factor: 17.745

View more
  8 in total

1.  Viral diseases and the brain: Long COVID puts the spotlight on how viral infections affect the brain: Long COVID puts the spotlight on how viral infections affect the brain.

Authors:  Philip Hunter
Journal:  EMBO Rep       Date:  2021-11-29       Impact factor: 8.807

2.  Genomics serology to inform therapies and vaccines for arthritogenic alphaviruses.

Authors:  Adolfo García-Sastre
Journal:  Proc Natl Acad Sci U S A       Date:  2021-10-12       Impact factor: 11.205

3.  Chikungunya virus assembly and budding visualized in situ using cryogenic electron tomography.

Authors:  David Chmielewski; Michael F Schmid; Graham Simmons; Jing Jin; Wah Chiu
Journal:  Nat Microbiol       Date:  2022-06-30       Impact factor: 30.964

4.  Development of a next-generation chikungunya virus vaccine based on the HydroVax platform.

Authors:  Dawn K Slifka; Hans-Peter Raué; Whitney C Weber; Takeshi F Andoh; Craig N Kreklywich; Victor R DeFilippis; Daniel N Streblow; Mark K Slifka; Ian J Amanna
Journal:  PLoS Pathog       Date:  2022-07-05       Impact factor: 7.464

5.  Two Conserved Phenylalanine Residues in the E1 Fusion Loop of Alphaviruses Are Essential for Viral Infectivity.

Authors:  Cormac J Lucas; Bennett J Davenport; Kathryn S Carpentier; Alex N Tinega; Thomas E Morrison
Journal:  J Virol       Date:  2022-04-13       Impact factor: 6.549

6.  Neutralizing antibodies protect mice against Venezuelan equine encephalitis virus aerosol challenge.

Authors:  Natasha M Kafai; Lauren E Williamson; Elad Binshtein; Soila Sukupolvi-Petty; Christina L Gardner; Jaclyn Liu; Samantha Mackin; Arthur S Kim; Nurgun Kose; Robert H Carnahan; Ana Jung; Lindsay Droit; Douglas S Reed; Scott A Handley; William B Klimstra; James E Crowe; Michael S Diamond
Journal:  J Exp Med       Date:  2022-03-17       Impact factor: 17.579

7.  Exposing cryptic epitopes on the Venezuelan equine encephalitis virus E1 glycoprotein prior to treatment with alphavirus cross-reactive monoclonal antibody allows blockage of replication early in infection.

Authors:  Amanda E Calvert; Susan L Bennett; Ann R Hunt; Rachel H Fong; Benjamin J Doranz; John T Roehrig; Carol D Blair
Journal:  Virology       Date:  2021-09-28       Impact factor: 3.616

Review 8.  The Viral Class II Membrane Fusion Machinery: Divergent Evolution from an Ancestral Heterodimer.

Authors:  Pablo Guardado-Calvo; Félix A Rey
Journal:  Viruses       Date:  2021-11-26       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.